

## Biotin anti-mouse CD3 $\epsilon$ Antibody

<b>Catalog# / Size</b>	100303 / 50 $\mu$ g 100304 / 500 $\mu$ g
<b>Clone</b>	145-2C11
<b>Regulatory Status</b>	RUO
<b>Other Names</b>	CD3 $\epsilon$ , T3, CD3
<b>Isotype</b>	Armenian Hamster IgG
<b>Description</b>	CD3 $\epsilon$ is a 20 kD transmembrane protein, also known as CD3 or T3. It is a member of the Ig superfamily and primarily expressed on T cells, NK-T cells, and at different levels on thymocytes during T cell differentiation. CD3 $\epsilon$ forms a TCR complex by associating with the CD3 $\delta$ , $\gamma$ and $\zeta$ chains, as well as the TCR $\alpha/\beta$ or $\gamma/\delta$ chains. CD3 plays a critical role in TCR signal transduction, T cell activation, and antigen recognition by binding the peptide/MHC antigen complex.

### Product Details

<b>Verified Reactivity</b>	Mouse
<b>Antibody Type</b>	Monoclonal
<b>Host Species</b>	Armenian Hamster
<b>Immunogen</b>	H-2K <sup>b</sup> -specific mouse cytotoxic T lymphocyte clone BM10-37
<b>Formulation</b>	Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
<b>Preparation</b>	The antibody was purified by affinity chromatography, and conjugated with biotin under optimal conditions.
<b>Concentration</b>	0.5 mg/ml
<b>Storage &amp; Handling</b>	The antibody solution should be stored undiluted between 2°C and 8°C. <b>Do not freeze.</b>
<b>Application</b>	<a href="#">FC - Quality tested</a> <a href="#">IHC-F - Verified</a>
<b>Recommended Usage</b>	Each lot of this antibody is quality control tested by <a href="#">immunofluorescent staining with flow cytometric analysis</a> . For flow cytometric staining, the suggested use of this reagent is $\leq 0.25 \mu\text{g}$ per $10^6$ cells in 100 $\mu\text{l}$ . For immunohistochemistry, a concentration range of 5.0 - 10 $\mu\text{g}/\text{mL}$ is suggested. It is recommended that the reagent be titrated for optimal performance for each application.
<b>Application Notes</b>	Clone 145-2C11 is useful for <i>in vitro</i> blocking of target-specific CTL-mediated cell lysis <sup>1</sup> , as well as T cell activation assays, inducing proliferation and cytokine production <sup>1,2,7,12,16</sup> . It also induces apoptosis in immature thymocytes <sup>32</sup> , and <i>in vivo</i> T cell depletion <sup>8-10</sup> . Additional reported applications (for relevant formats of this clone) include: immunoprecipitation <sup>1</sup> , immunohistochemical staining <sup>14,15</sup> of acetone-fixed frozen sections and zinc-fixed paraffin-embedded sections, Western blotting <sup>4</sup> , complement-mediated cytotoxicity <sup>6</sup> , <i>in vitro</i> and <i>in vivo</i> stimulation of T cells <sup>1,2,7,12,16</sup> , immunofluorescent staining <sup>5</sup> , and <i>in vivo</i> T cell depletion <sup>8-10</sup> . The 145-2C11 antibody has been reported to block the binding of 17A2 antibody to CD3 epsilon-specific T cells <sup>11</sup> . Clone 145-2C11 is not recommended for formalin-fixed paraffin embedded sections. The LEAF™ purified antibody (Endotoxin <0.1 EU/ $\mu\text{g}$ , Azide-Free, 0.2 $\mu\text{m}$ filtered) is recommended for functional assays (Cat. No. 100314). For <i>in vivo</i> studies or highly sensitive assays, we recommend Ultra-LEAF™ purified antibody (Cat. No. 100340) with a lower endotoxin limit than standard LEAF™ purified antibodies (Endotoxin <0.01 EU/ $\mu\text{g}$ ).
<b>Application References</b>	<ol style="list-style-type: none"> <li>1. Leo O, et al. 1987. <i>P. Natl. Acad. Sci. USA</i> 84:1374. (IP, Activ, Block)</li> <li>2. Kruisbeek AM, et al. 1991. <i>In Current Protocols in Immunology</i>. 3.12.1. (Activ)</li> <li>3. Duke RC, et al. 1995. <i>Current Protocols in Immunology</i>. 3.17.1.</li> <li>4. Salvadori S, et al. 1994. <i>J. Immunol.</i> 153:5176. (WB)</li> <li>5. Payer E, et al. 1991. <i>J. Immunol.</i> 146:2536. (IF)</li> <li>6. Jacobs H, et al. 1994. <i>Eur. J. Immunol.</i> 24:934. (CMCD)</li> </ol>

7. Vossen ACTM, *et al.* 1995. *Eur. J. Immunol.* 25:1492. (Activ)
8. Henrickson M, *et al.* 1995. *Transplantation* 60:828. (Deplete)
9. Kinnaert P, *et al.* 1996. *Transpl. Int.* 9:386. (Deplete)
10. Han WR, *et al.* 1999. *Transpl. Immunol.* 7:207. (Deplete)
11. Miescher GC, *et al.* 1989. *Immunol. Lett.* 23:113. (Block)
12. Terrazas LI, *et al.* 2005. *Intl. J. Parasitology.* 35:1349. (Activ)
13. Ko SY, *et al.* 2005. *J. Immunol.* 175:3309.
14. Podd BS, *et al.* 2006. *J. Immunol.* 176:6532. (IHC-F)
15. Tilley SL, *et al.* 2007. *J. Immunol.* 178:3208. (IHC-F)
16. Wang W, *et al.* 2007. *J. Immunol.* 178:4885. (Activ)
17. Xiao S, *et al.* 2007. *J. Exp. Med.* 204:1691.
18. Chappaz S, *et al.* 2007. *Blood* doi:10.1182/blood-2007-02-074245. (FC) [PubMed](#).
19. Curtsinger JM, *et al.* 2005. *J. Immunol.* 175:4392. [PubMed](#)
20. Guo Y, *et al.* 2008. *Blood* 112:480. [PubMed](#)
21. Kenna TJ, *et al.* 2008. *Blood* 111:2091.
22. Perchonock CE, *et al.* 2007. *J. Immunol.* 179:1768. [PubMed](#)
23. Perchonock GE, *et al.* 2006. *Mol. Cell. Biol.* 26:6005. [PubMed](#)
24. Kanaya T, *et al.* 2008. *Am. J. Physiol. Gastrointest. Liver Physiol.* 295:G273. [PubMed](#)
25. de Koning BA, *et al.* 2006. *Int. Immunol.* 18:941. [PubMed](#)
26. Schulteis RD, *et al.* 2008. *Blood* 295:G273. [PubMed](#)
27. Qi Q, *et al.* 2009. *Blood* 114:564. [PubMed](#)
28. Helmersson S, *et al.* 2013. *Am J Pathol.* 9440:123. [PubMed](#)
29. Wu S, *et al.* 2014. *Clin Vaccine Immunol.* 21:156. [PubMed](#)
30. Yan J, *et al.* 2014. *Vaccine.* 32:2833. [PubMed](#)
31. Guiterrez DA, *et al.* 2014. *Diabetes.* 63:3827. [PubMed](#)
32. Shi YF, *et al.* 1991. *J Immunol.* 146:3340. (Apop)

## Product Citations

1. Suzuki M, *et al.* 2015. *J Immunol.* 195: 1273-1281. [PubMed](#)
2. Doisne J, *et al.* 2015. *J Immunol.* 195: 3937 - 3945.. [PubMed](#)
3. Logan K Smith *et al.* 2018. *Immunity.* 48(2):299-312 . [PubMed](#)
4. Grigsby SM, *et al.* 2021. *Cancers (Basel).* 13:. [PubMed](#)
5. Davis FM, *et al.* 2020. *J Immunol.* 2503:204. [PubMed](#)
6. Kim S, *et al.* 2020. *Immunity.* 53(4):759-774.e9. [PubMed](#)
7. Domingues AF, *et al.* 2020. *Elife.* 9:e51754. [PubMed](#)
8. Roco JA *et al.* 2019. *Immunity.* 51(2):337-350 . [PubMed](#)
9. Tanimura N *et al.* 2018. *Developmental cell.* 46(5):581-594 . [PubMed](#)
10. Schloss MJ, *et al.* 2022. *Nat Immunol.* 23:605. [PubMed](#)
11. Lin YH, *et al.* 2021. *Front Immunol.* 12:626418. [PubMed](#)
12. Riether C, *et al.* 2021. *Cell Reports.* 34(4):108663. [PubMed](#)
13. Giambra V *et al.* 2018. *Cell stem cell.* 23(5):714-726 . [PubMed](#)
14. Sasse C, *et al.* 2022. *Pathogens.* 11:. [PubMed](#)
15. de Mingo Pulido , *et al.* 2021. *Immunity.* 54(6):1154-1167.e7. [PubMed](#)
16. Álvaro de Mingo Pulido *et al.* 2018. *Cancer cell.* 33(1):60-74 . [PubMed](#)
17. Bowers E, *et al.* 2018. *Nat Med.* 24:95. [PubMed](#)
18. Klarquist J, *et al.* 2021. *Cell Rep.* 36:109591. [PubMed](#)
19. Hinterbrandner M, *et al.* 2021. *JCI Insight.* 6:e151797. [PubMed](#)
20. Lu SX, *et al.* 2021. *Cell.* . [PubMed](#)
21. Liu X, *et al.* 2021. *eLife.* 0.416666666666667. [PubMed](#)
22. Li Q *et al.* 2018. *Immunity.* 48(2):258-270 . [PubMed](#)
23. Mann M, *et al.* 2018. *Cell Rep.* 25:2992. [PubMed](#)
24. Davis FM, *et al.* 2019. *Arterioscler Thromb Vasc Biol.* 39:2353. [PubMed](#)
25. Olsson A, *et al.* 2016. *Nature.* 10.1038/nature19348. [PubMed](#)
26. Lim H, *et al.* 2015. *J Immunol.* 195: 5432 - 5439. [PubMed](#)
27. Kimball A, *et al.* 2018. *Arterioscler Thromb Vasc Biol.* 38:1102. [PubMed](#)
28. She L, *et al.* 2021. *JCI Insight.* 6:e143509. [PubMed](#)
29. Paiva RS, *et al.* 2021. *Eur J Immunol.* 51:1968. [PubMed](#)
30. Kurkewich J, *et al.* 2016. *PLoS One.* 11: 0161468. [PubMed](#)
31. Jassinskaja M, *et al.* 2021. *Cell Reports.* 34(12):108894. [PubMed](#)
32. Paiva RA, *et al.* 2021. *Cell Reports.* 35(2):108967. [PubMed](#)
33. Köchl R, *et al.* 2020. *Elife.* 9:00. [PubMed](#)
34. Pearce V, *et al.* 2015. *J Immunol.* 195: 3206 - 3217. [PubMed](#)
35. Hurrell BP, *et al.* 2019. *Cell Rep.* 29:4509. [PubMed](#)
36. Kimball AS *et al.* 2019. *Immunity.* 51(2):258-271 . [PubMed](#)
37. Onodera T, *et al.* 2019. *J Immunol.* 203:3282. [PubMed](#)
38. Matsumura T *et al.* 2019. *Cell Rep.* 27(2):561-571 . [PubMed](#)
39. Lopez DA, *et al.* 2022. *Cell Rep.* 41:111677. [PubMed](#)
40. Kotaki R, *et al.* 2020. *Sci Rep.* 10:13554. [PubMed](#)
41. Derecka M, *et al.* 2020. *Nat Immunol.* 261:21. [PubMed](#)
42. Kim O, *et al.* 2017. *Nat Commun.* 10.1038/s41467-017-00729-8. [PubMed](#)
43. Progatzy F, *et al.* 2021. *Nature.* 599:125. [PubMed](#)
44. Opejin A, *et al.* 2020. *Cell Reports.* 33(8):108424. [PubMed](#)
45. Frodermann V, *et al.* 2019. *Nat Med.* 25:1761. [PubMed](#)
46. , *et al.* 2021. *Eur J Immunol.* 51:2708. [PubMed](#)
47. Onodera T, *et al.* 2021. *Immunity.* 54:2385. [PubMed](#)
48. Perez E, *et al.* 2020. *J Immunol.* 205:2489. [PubMed](#)
49. Trefzer A, *et al.* 2021. *Cell Reports.* 34(6):108748. [PubMed](#)
50. Blanchard A, *et al.* 2021. *Nat Commun.* 12:4693. [PubMed](#)
51. Pariser DN, *et al.* 2021. *J Clin Invest.* 131:00:00. [PubMed](#)

52. Fournier M, Bijl C 2015. *Stem Cells Dev.* 24: 2413-2422. [PubMed](#)
53. Galle-Treger L, *et al.* 2020. *J Allergy Clin Immunol.* 145:502. [PubMed](#)
54. Galle-Treger L, *et al.* 2019. *Nat Commun.* 10:713. [PubMed](#)
55. Balzano M *et al.* 2019. *Cell reports.* 26(12):3257-3271. [PubMed](#)
56. Goldstein JM *et al.* 2019. *Cell reports.* 27(4):1254-1264. [PubMed](#)
57. Wuggenig P, *et al.* 2020. *Commun Biol.* 3:130. [PubMed](#)
58. Wolf SJ, *et al.* 2022. *JCI Insight.* 7: [PubMed](#)
59. Honda H, *et al.* 2014. *J Leukoc Biol.* 96:1087. [PubMed](#)
60. Liao G, *et al.* 2010. *Int Immunol.* 1.096527778. [PubMed](#)
61. Zeis P, *et al.* 2020. *Immunity.* 53:775. [PubMed](#)
62. Kimball AS, *et al.* 2020. *Thromb Haemost.* 120:289. [PubMed](#)
63. Adachi Y, *et al.* 2019. *Nat Commun.* 10:3883. [PubMed](#)
64. Nagashima H *et al.* 2019. *Immunity.* 51(4):682-695. [PubMed](#)
65. van der Poel CE, *et al.* 2019. *Cell Rep.* 29:2745. [PubMed](#)
66. Murata T, *et al.* 2020. *Sci Rep.* 10:13560. [PubMed](#)
67. Koide S, *et al.* 2022. *iScience.* 25:103603. [PubMed](#)
68. Miyauchi K, *et al.* 2021. *Nat Commun.* 12:3789. [PubMed](#)
69. Park DS, *et al.* 2019. *PLoS Comput Biol.* 15:e1006913. [PubMed](#)
70. Yoshida H, *et al.* 2019. *Cell.* 176:897. [PubMed](#)
71. Mohrin M, *et al.* 2021. *Aging Cell.* 20:e13313. [PubMed](#)
72. Anderson DA, *et al.* 2022. *J Exp Med.* 219: [PubMed](#)
73. Wagner AK, *et al.* 2022. *iScience.* 25:105137. [PubMed](#)
74. Riedel SS, *et al.* 2021. *Molecular Cell.* 81(11):2332-2348.e9. [PubMed](#)
75. Lutz J, *et al.* 2015. *Nat Commun.* 6: 8575. [PubMed](#)
76. Matsuzaki Y, *et al.* 2015. *Biomed Rep.* 1: 91 - 97. [PubMed](#)
77. Han P, *et al.* 2020. *Sci Adv.* 6:eaaz1580. [PubMed](#)
78. Luo H, *et al.* 2019. *Cell Rep.* 26:945. [PubMed](#)
79. Ho K, *et al.* 2014. *Cell Death Dis.* 5:1518. [PubMed](#)
80. Bieber K, *et al.* 2016. *Sci Rep.* 6:38357. [PubMed](#)
81. Heyde A, *et al.* 2021. *Cell.* 184(5):1348-1361.e22. [PubMed](#)
82. Li ZG, *et al.* 2020. *Chin Med J (Engl).* 1943:133. [PubMed](#)
83. O'Boyle C, *et al.* 2020. *Int J Stroke.* 0.746527778. [PubMed](#)
84. Bae S, *et al.* 2021. *Cell Reports.* 35(11):109264. [PubMed](#)
85. Zysset D, *et al.* 2016. *Nat Commun.* 7:13151. [PubMed](#)
86. Muro R, *et al.* 2015. *PLoS One.* 10:119898. [PubMed](#)
87. Johnson JL *et al.* 2018. *Immunity.* 48(2):243-257. [PubMed](#)
88. Deets KA, *et al.* 2021. *Elife.* 10: [PubMed](#)
89. Cielas DP, *et al.* 2022. *STAR Protoc.* 3:101464. [PubMed](#)
90. Davis FM, *et al.* 2021. *J Exp Med.* 218: [PubMed](#)

**RRID** AB\_312668 (BioLegend Cat. No. 100303)  
 AB\_312669 (BioLegend Cat. No. 100304)

## Antigen Details

---

<b>Structure</b>	Ig superfamily, forms CD3/TCR complex with CD3 $\delta$ , $\gamma$ and $\zeta$ subunits and TCR ( $\alpha/\beta$ and $\gamma/\delta$ ), 20 kD
<b>Distribution</b>	Thymocytes (differentiation dependent), mature T cells, NK-T cells
<b>Function</b>	TCR signal transduction, T cell activation, antigen recognition
<b>Ligand/Receptor</b>	Peptide antigen/MHC-complex
<b>Cell Type</b>	NKT cells, T cells, Thymocytes, Tregs
<b>Biology Area</b>	Immunology
<b>Molecular Family</b>	CD Molecules, TCRs
<b>Antigen References</b>	<ol style="list-style-type: none"> <li>1. Barclay A, <i>et al.</i> 1997. <i>The Leukocyte Antigen FactsBook</i> Academic Press.</li> <li>2. Davis MM. 1990. <i>Annu. Rev. Biochem.</i> 59:475.</li> <li>3. Weiss A, <i>et al.</i> 1994. <i>Cell</i> 76:263.</li> </ol>
<b>Gene ID</b>	<a href="#">12501</a>

## Related Protocols

---

[Immunohistochemistry Protocol for Frozen Sections](#)

[Cell Surface Flow Cytometry Staining Protocol](#)


## Other Formats

---


APC anti-mouse CD3 $\epsilon$ , Biotin anti-mouse CD3 $\epsilon$ , FITC anti-mouse CD3 $\epsilon$ , PE anti-mouse CD3 $\epsilon$ , PE/Cyanine5 anti-mouse CD3 $\epsilon$ , Purified anti-mouse CD3 $\epsilon$ , PE/Cyanine7 anti-mouse CD3 $\epsilon$ , Alexa Fluor® 488 anti-mouse CD3 $\epsilon$ , Alexa Fluor® 647 anti-mouse CD3 $\epsilon$ , PerCP anti-mouse CD3 $\epsilon$ , PerCP/Cyanine5.5 anti-mouse CD3 $\epsilon$ , Purified anti-mouse CD3 $\epsilon$  (Maxpar® Ready), APC/Cyanine7 anti-mouse CD3 $\epsilon$ , Pacific Blue™ anti-mouse CD3 $\epsilon$ , Brilliant Violet 421™ anti-mouse CD3 $\epsilon$ , Ultra-LEAF™ Purified anti-mouse CD3 $\epsilon$ , PE/Dazzle™ 594 anti-mouse CD3 $\epsilon$ , Brilliant Violet 510™ anti-mouse CD3 $\epsilon$ , Brilliant Violet 605™ anti-mouse CD3 $\epsilon$ , Brilliant Violet 711™ anti-mouse CD3 $\epsilon$ , Brilliant Violet 785™ anti-mouse CD3 $\epsilon$ , APC/Fire™ 750 anti-mouse CD3 $\epsilon$ , GolnVivo™ Purified anti-mouse CD3 $\epsilon$ , Spark YG™ 593 anti-mouse CD3

## Product Data

---



C57BL/6 mouse splenocytes were stained with biotinylated CD3 $\epsilon$  (clone 145-2C11) (filled histogram) or Armenian hamster IgG isotype control (open histogram), followed by Sav-PE.



C57BL/6 mouse frozen spleen section was fixed with 4% paraformaldehyde (PFA) for 10 minutes at room temperature and blocked with 5% FBS for 30 minutes at room temperature. Then the section was stained with 10  $\mu$ g/ml of biotin anti-mouse CD3 $\epsilon$  (clone 145-2C11), Alexa Fluor® 594 anti-mouse B220 (clone RA3-6B2) (blue), and Alexa Fluor® 488 anti-mouse CD29 (clone HM $\beta$ 1-1) (green) overnight at 4°C, followed by 2.5  $\mu$ g/ml of Spark YG™ 570 Streptavidin (red) for 2 hours at room temperature. The image was captured by 10X objective.

For research use only. Not for diagnostic use. Not for resale. BioLegend will not be held responsible for patent infringement or other violations that may occur with the use of our products.

\*These products may be covered by one or more Limited Use Label Licenses (see the BioLegend Catalog or our website, [www.biolegend.com/ordering#license](http://www.biolegend.com/ordering#license)). BioLegend products may not be transferred to third parties, resold, modified for resale, or used to manufacture commercial products, reverse engineer functionally similar materials, or to provide a service to third parties without written approval of BioLegend. By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses. Unless otherwise indicated, these products are for research use only and are not intended for human or animal diagnostic, therapeutic or commercial use.

BioLegend Inc., 8999 BioLegend Way, San Diego, CA 92121 [www.biolegend.com](http://www.biolegend.com)  
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587